Washington Post, September 19, 2016. Despite lack of proof that the drug will help patients, FDA approves a controversial drug. NCHR president Diana Zuckerman asks “is there any drug the FDA won’t approve?”
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
Feds to Crack Down on Those Who Fail to Report Clinical Trials
Politico Pro, September 16, 2016. Drug companies and research institutions will have to publicly report more clinical trial data, including results that show their products or experiments failed, under new policies rolled out Friday by HHS. But NCHR president criticizes their decision not to provide summaries of treatment results that patients can understand.
Read More »Doctors Downplaying Drug’s Suicide Risks Attract FDA’s Scrutiny
Bloomberg, September 13, 2016. The U.S. Food and Drug Administration has a message for doctors: The money you’re taking from pharmaceutical companies may be clouding your judgment. NCHR president Dr. Diana Zuckerman points out questions about the accuracy of safety data submitted by Pfizer about Chantix, the smoking cessation drug.
Read More »Medical Devices Approved Using Low-Quality Data Affect Medicare Costs
Bloomberg BNA, September 8, 2016. High-risk medical devices are sometimes approved using low-quality clinical data and this increases Medicare costs, a member of a Medicare congressional advisory panel said Sept. 8. “I agree completely” says Dr. Diana Zuckerman of NCHR
Read More »The ‘Grassroots Campaign’ for ‘Female Viagra’ Was Actually Funded by Its Manufacturer
New York Magazine’s The Cut, September 8, 2016. The “It” drug was Addyi, Sprout Pharmaceutical’s answer to low libido in women, approved by the FDA last August and now in the news for its low sales and for turning out to be a bit of a dud, effectiveness-wise.
Read More »